Ubiquinone-1
(Synonyms: 辅酶Q1) 目录号 : GC30723Ubiquinone-1是辅酶Q合成过程中的中间体。
Cas No.:727-81-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ubiquinone-1 is an intermediate in the biosynthetic pathway of coenzyme Q[1]. Ubiquinone-1 is mainly reduced to ubiquinol by the action of complex I and II in the mitochondrial respiratory chain, acting as an electron carrier in the inner mitochondrial membrane to mediate electron transfer within the aerobic respiratory chain, promote oxidative phosphorylation and generate ATP and energy for cells[2]. Ubiquinone-1 also plays a role in antioxidant defense by scavenging reactive oxygen species (ROS) and reducing oxidative stress damage[3]. Ubiquinone-1 is usually used in research on energy metabolism and neurological diseases, immune system diseases[4][5].
In vitro, treatment of rat pulmonary microvascular endothelial cells (PMVEC) cultured in low glucose medium with Ubiquinone-1 (10µM; 6h) prevented ATP depletion, mitochondrial membrane depolarization, and increased monolayer permeability caused by the complex I inhibitor rotenone[6]. Treatment of primary rat astrocyte cultures with Ubiquinone-1 (5µM; 30min) significantly inhibited the recycling of ascorbate from dehydroascorbic acid (DHAA) in a dose-dependent manner under glucose-free conditions[7].
References:
[1] Fato R, Estornell E, Di Bernardo S, Pallotti F, Parenti Castelli G, Lenaz G. Steady-state kinetics of the reduction of coenzyme Q analogs by complex I (NADH:ubiquinone oxidoreductase) in bovine heart mitochondria and submitochondrial particles. Biochemistry. 1996;35(8):2705-2716.
[2] Mantle D, Dewsbury M, Hargreaves IP. The Ubiquinone-Ubiquinol Redox Cycle and Its Clinical Consequences: An Overview. Int J Mol Sci. 2024;25(12):6765.
[3] Olaru G, Buga AM, Sandu RE, Padureanu V, Popa DG, Calina D. Harnessing Mitochondrial Function for Post-Stroke Rehabilitation: Unlocking Antioxidant Power. Antioxidants (Basel). 2025;14(9):1080.
[4] Roginsky VA, Mohr D, Stocker R. Reduction of ubiquinone-1 by ascorbic acid is a catalytic and reversible process controlled by the concentration of molecular oxygen. Redox Rep. 1996;2(1):55-62.
[5] Rauchova H. Coenzyme Q10 effects in neurological diseases. Physiol Res. 2021;70(Suppl4):S683-S714.
[6] Bongard RD, Townsley MI, Merker MP. The effects of mitochondrial complex I blockade on ATP and permeability in rat pulmonary microvascular endothelial cells in culture (PMVEC) are overcome by coenzyme Q1 (CoQ1). Free Radic Biol Med. 2015;79:69-77.
[7] Dragan M, Dixon SJ, Jaworski E, Chan TS, O'brien PJ, Wilson JX. Coenzyme Q(1) depletes NAD(P)H and impairs recycling of ascorbate in astrocytes. Brain Res. 2006;1078(1):9-18.
Ubiquinone-1是辅酶Q合成过程中的中间体[1]。Ubiquinone-1主要通过细胞呼吸链中的复合体I和II的作用被还原为Ubiquinol，在线粒体内膜中作为电子载体，介导有氧呼吸链内的电子传递，促进氧化磷酸化，生成ATP，为细胞提供能量[2]。Ubiquinone-1还通过清除活性氧（ROS）和减少氧化应激损伤在抗氧化防御中发挥作用[3]。Ubiquinone-1通常用于能量代谢以及神经系统疾病、免疫系统疾病的研究[4][5]。
在体外实验中，用Ubiquinone-1（10µM；6小时）处理低葡萄糖培养基中的大鼠肺微血管内皮细胞（PMVEC），可阻止由复合体I抑制剂鱼藤酮引起的ATP耗竭、线粒体膜电位去极化以及单层通透性增加[6]。在无葡萄糖条件下，用Ubiquinone-1（5µM；30分钟）处理原代大鼠星形胶质细胞培养物，以剂量依赖的方式显著抑制脱氢抗坏血酸（DHAA）到抗坏血酸的再循环[7]。
| Cell experiment [1]: | |
Cell lines | rat pulmonary microvascular endothelial cells (PMVEC) |
Preparation Method | Rat pulmonary microvascular endothelial cells (PMVEC) were grown in DMEM containing 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin, and 30mg/ml L-glutamine on either 6-well gelatin-coated (2% w/w) plastic cell culture dishes, on gelatin-coated (2% vol/wt) Biosilon (polystyrene) microcarrier beads (230mm mean diameter; 160cm2/ml beads) or on commercially available collagen-coated transwell inserts. Confluent monolayers of PMVEC in individual wells of 6-well culture dishes (for ATP measurements), or on microcarrier beads (for Δψm or O2 consumption measurements) were washed free of culture medium three times in Hanks balanced salt solution containing 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, warmed to 37℃ (HBSS/Hepes). The HBSS/Hepes contained 0.2mM glucose plus 5.3mM mannitol (low glucose). Experimental treatments were administered in the HBSS/Hepes at 37℃ over a 6h time course. The concentrations of each substance, used either alone or in combination, were rotenone (0.5μM), Ubiquinone-1 (10μM). PMVEC ATP levels were measured using the ATPlite kit. Mitochondrial membrane potential (Δψm) measurements were made using TMRE as the Δψm sensitive dye. |
Reaction Conditions | 10µM; 6h |
Applications | Treatment of rat pulmonary microvascular endothelial cells (PMVEC) cultured in low glucose medium with Ubiquinone-1 prevented ATP depletion and mitochondrial membrane depolarization caused by the complex I inhibitor rotenone. |
References: | |
| Cas No. | 727-81-1 | SDF | |
| 别名 | 辅酶Q1 | ||
| 化学名 | 2,3-dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-2,5-cyclohexadiene-1,4-dione | ||
| Canonical SMILES | O=C1C(OC)=C(OC)C(C(C)=C1C/C=C(C)\C)=O | ||
| 分子式 | C14H18O4 | 分子量 | 250.29 |
| 溶解度 | DMF: 10 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9954 mL | 19.9768 mL | 39.9537 mL |
| 5 mM | 799.1 μL | 3.9954 mL | 7.9907 mL |
| 10 mM | 399.5 μL | 1.9977 mL | 3.9954 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet